No registrations found.
ID
Source
Brief title
Health condition
metastatic prostate cancer
Sponsors and support
Intervention
Outcome measures
Primary outcome
The rate of mPC patients with quantifiable ctDNA taken pre-treatment.
Secondary outcome
- The percentage of blood samples with sufficient ctDNA.
- The interval between detected ctDNA and PSA response during treatment.
- The correlation between ctDNA response and progression-free survival.
Study objective
With the quantification of circulating tumor DNA treatment response assessment will improve in metastatic prostate cancer patients.
Study design
Enrolment should be completed within 3 years.
Intervention
Repeated blood drawns and urine collection
L.F. van Dessel
Postbus 2040
Rotterdam 3000 CA
The Netherlands
Tel.: 010-7044375
E-mail: l.vandessel@erasmusmc.nl
L.F. van Dessel
Postbus 2040
Rotterdam 3000 CA
The Netherlands
Tel.: 010-7044375
E-mail: l.vandessel@erasmusmc.nl
Inclusion criteria
- Histologically or cytologically confirmed adenocarcinoma of the prostate.
- Measurable metastatic lesion(s) according to PCWG2 and/or RECIST 1.1 criteria
- Intention to start (new) line of systemic treatment
- Written informed consent
- Willingness and capacity to follow the protocol specified visits for blood sampling for the total duration of the study.
- Age ≥ 18 years.
- WHO performance status ≤2.
- Concurrent participation in CPCT-02 study
Exclusion criteria
NA
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL5625 |
| NTR-old | NTR5732 |
| Other | : MEC-2016-081 |